Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AnGes's change in inventory for the quarter that ended in Jun. 2026 was 円0.0 Mil. It means AnGes's inventory
stayed the same
from Mar. 2026 to Jun. 2026 .
AnGes's change in inventory for the fiscal year that ended in Dec. 2025 was 円-317.3 Mil. It means AnGes's inventory
increased by 円317.3 Mil
from Dec. 2024 to Dec. 2025 .
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Inventory Turnover measures how fast the company turns over its inventory within a year.
AnGes's Inventory Turnover for the quarter that ended in Jun. 2026 was 0.00.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
AnGes's Inventory to Revenue for the quarter that ended in Jun. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AnGes Change In Inventory Related Terms
AnGes Change In Inventory Historical Data
* Premium members only.
The historical data trend for AnGes's Change In Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.
Change In Inventory for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円0.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AnGes (TSE:4563) has a Change In Inventory of 円0.0 Mil as of Jun. 2026. Change in Inventory is the difference between current-period inventory and past-period inventory. View historical data for AnGes and its competitors.
Is AnGes' Change In Inventory too high?
AnGes' current Change In Inventory is 円0.0 Mil. Overall, AnGes has a GF Score™ of 51/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does AnGes' Change In Inventory compare to VRTX and REGN?
AnGes' Change In Inventory of 円0.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Inventory for a Biotechnology company?
A good Change In Inventory depends on the Biotechnology industry context. However, Change In Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Inventory mean?
A high Change In Inventory can signal that a stock is expensive relative to its fundamentals. Change in Inventory is the difference between current-period inventory and past-period inventory. View historical data for AnGes and its competitors. AnGes's current Change In Inventory is 円0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AnGes stock overvalued right now?
Based on GuruFocus' analysis, AnGes (TSE:4563) is currently considered Fairly Valued. The stock's GF Value™ is 円49.93, compared to a current price of 円50.00 — trading 0.1% above its estimated fair value. The current Change In Inventory is 円0.0 Mil. AnGes' overall GF Score™ is 51/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Inventory calculated?
Change In Inventory is calculated from a company's financial statements. For AnGes (TSE:4563), the current Change In Inventory is 円0.0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AnGes (TSE:4563) Overvalued in 2026?
Based on GuruFocus' analysis, AnGes stock appears to be overvalued.
The current stock price of 円50.00 is trading 0.1% above its estimated GF Value™ of 円49.93.
GuruFocus considers AnGes to be Fairly Valued.
Key valuation signals for TSE:4563:
Change In Inventory: 円0.0 Mil
GF Value™: 円49.93 vs. price of 円50.00 (0.1% above fair value)
No single metric tells the full story. See the TSE:4563 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AnGes Inc is a biopharmaceutical company. The company is involved in research and development and sales of pharmaceuticals such as gene-based drugs (gene therapy products, nucleic acid drugs); contract testing for rare genetic diseases, etc.
51GF Score
Get the complete analysis for TSE:4563
Change In Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4563 has been successfully added to your 
